NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Coeptis Therapeutics Holdings Inc (COEP) Stock Analysis

Coeptis Therapeutics Holdings Inc (COEP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

COEP

$16.40

+$0.19 (+1.17%)

Last trade April 24, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COEP with… →

COEP Key Statistics

As of Apr 24, 2026
Trading
Open
$16.23
Previous Close
$16.21
Day's Range
15.87–17.27
52-Week Range
6.80–21.41
Volume
111.93K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.43
Valuation
Market Cap
$102.06M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
74.88
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.81
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+31.52%
Dividend and dates
Avg Volume
51.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COEP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.09%
2025+159.09%
2024 (partial year)+89.66%

As of April 24, 2026.

COEP Valuation vs Biotechnology Median

Median of 656 stocks
MetricCOEPBiotechnology medianvs median
P/S ratio74.8815.264.9x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Coeptis Therapeutics Holdings Inc (COEP) at $102.06M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 4.

Over the past 52 weeks the price has ranged from $6.80 to $21.41. COEP last closed at $16.40 on April 24, 2026. That is +$0.19 (+1.17%) against the previous close. The latest close sits 141.18% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $1.36M. The reported profit margin is 0%. Trailing earnings per share are −2.81.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 74.88 times revenue. On price-to-sales that is 4.9 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at −0.43. Daily returns over the trailing 1 year annualize to a volatility of 90.13%. Over the trailing twelve months the price has returned +31.52%.

Growth & Income

The record shows no dividend for COEP.

The record holds one complete calendar year, 2025, which returned +159.09%. So far in 2026 the price is +15.09%.

Peer Comparison

Coeptis Therapeutics Holdings Inc (COEP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Coeptis Therapeutics Holdings Inc COEP $102.06M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Coeptis Therapeutics Holdings Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of April 24, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Coeptis Therapeutics Holdings Inc

As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Visit website →